Specialty Drug Delivery Firm Integral BioSystems LLC Exhibiting at ARVO 2013 Gathering in Seattle, WA
Integral BioSystems will exhibit and offer its drug development expertise to attendees at the ARVO Annual Meeting at the Washington State Convention Center in Seattle, WA from May 5, 2013 through May 9, 2013 in Exhibitor Booth #517.
Bedford, MA (PRWEB) May 05, 2013
The 2013 Meeting of the Association for Research and Vision in Ophthalmology, being held at the Washington State Convention Center in Seattle, WA combines a wide range of talks from commercial and academic figures in ophthalmological science, poster presentations about recent developments in ophthalmology, and offers of ophthalmology-related products and services. Integral BioSystems LLC, led by 20+ year veteran of drug formulation development Shikha P. Barman, Ph.D. and VP of Operations/Intellectual Property Dave Karasic, Esq., will be on hand to answer questions about the firm and its capabilities, which include ophthalmological pharmaceutical formulation development and its related intellectual property issues.
Integral BioSystems´ niche is in developing nano-engineered drug delivery systems aimed at providing solutions to long-held issues in drug products, especially in low drug absorption by target tissues due to cell impermeability and insolubility. In addition to assisting drug companies in developing their dosage forms, Integral scientists are also working on novel solutions to improve the bioavailability of Class II, III and IV compounds, as well developing proprietary drug delivery platforms for both the front of the eye and back of the eye administration.
The Company has developed, and continues to develop, numerous dosage forms for ophthalmic administration routes. Integral BioSystems has a translational approach to drug development, customizing delivery systems to achieve the biologically effective objectives of the therapy. Dosage forms are customized to achieve sustained release or targeted, tissue-focused delivery or fast-release/instant delivery, depending upon the desired product attributes.
Once the drug-containing formulations are tested in preclinical models, the Company develops an integrated CMC plan to systematically transition the project to scale up and product development. As part of product development, Integral BioSystems specializes in efficiently developing a dosage form to manufacture and test in Phase I/Phase II first-in-man trials for proof-of-concept. The Company has a network of manufacturers/analytical houses for pharmaceutics that can fast-track the manufacture and release of the sterile dosage form for first-in-man trials.
The Company business model is based on the following corporate objectives: (a) to be a collaborating partner in formulation development/drug product design for start-up and small companies, taking concepts from the laboratory to the clinic, (b) to re-formulate approved drugs for better efficacy and safety profiles, (c) to be a collaborating partner with API synthesis companies to develop generic drug product formats and (d) offer corporate legal services such as contract development/negotiations, patent filings and assessment of IP portfolios.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/5/prweb10640523.htm